Sutro Biopharma (FRA:S09) Beginning Cash Position : €64.5 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Beginning Cash Position?

Sutro Biopharma's Beginning Cash Position for the quarter that ended in Mar. 2024 was €64.5 Mil.

Sutro Biopharma's quarterly Beginning Cash Position declined from Sep. 2023 (€221.1 Mil) to Dec. 2023 (€75.8 Mil) and declined from Dec. 2023 (€75.8 Mil) to Mar. 2024 (€64.5 Mil).

Sutro Biopharma's annual Beginning Cash Position declined from Dec. 2021 (€183.2 Mil) to Dec. 2022 (€29.5 Mil) but then increased from Dec. 2022 (€29.5 Mil) to Dec. 2023 (€44.1 Mil).

Sutro Biopharma Beginning Cash Position Historical Data

The historical data trend for Sutro Biopharma's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Beginning Cash Position Chart

Sutro Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

112.78

4.09

183.22

29.54

44.13

Sutro Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															44.95	58.47	221.10	75.84	64.53

Sutro Biopharma Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Sutro Biopharma Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Sutro Biopharma (FRA:S09) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (FRA:S09) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

STRO:USA S09:Germany

Address

111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.sutrobio.com

Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma (FRA:S09) Headlines

No Headlines